Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials

Lancet

Volumn 362, Issue 9395, 2003, Pages 1527-1535

  Turnbull, F ^a   Neal, B ^a   Algert, C ^a   Chalmers, J ^a   Woodward, M ^a   MacMahon, S ^a   Baigent, C ^a   Cutler, J ^a   Fagard, R ^a   Whelton, P ^a   Yusuf, S ^a   Chapman, N ^a   Agodoa, L ^a   Black, H ^a   Boissel, J P ^a   Brenner, B ^a   Brown, M ^a   Bulpitt, C ^a   Byington, R ^a   Collins, R ^a   Dahlof, B ^a   Davis, B ^a   Dens, J ^a   Estacio, R ^a   Fox, K ^a   Hansson, L ^a   Holman, R ^a   Hunsicker, L ^a   Kostis, J ^a   Kuramoto, K ^a   Lewis, E ^a   Lindholm, L ^a   Lubsen, J ^a   Malacco, E ^a   Mancia, G ^a   Pepine, C ^a   Pfeffer, M ^a   Pitt, B ^a   Poole Wilson, P ^a   Remuzzi, G ^a   Rodgers, A ^a   Ruggenenti, P ^a   Schrier, R ^a   Sever, P ^a   Sleight, P ^a   Staessen, J ^a   Teo, K ^a   Turner, R ^a   Wing, L ^a   Yui, Y ^a   Zanchetti, A ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; TRICHLORMETHIAZIDE; UNINDEXED DRUG; VERAPAMIL;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY RISK; DRUG DOSE REGIMEN; DRUG EFFECT; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; TREATMENT OUTCOME;

EID: 0242654867     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14739-3     Document Type: Article

References (52)

1. Murray C, Lopez A. The global burden of disease. Cambridge: Harvard University Press, 1996.
2. WHO. World health report 2002; reducing risk, promoting healthy life. Geneva: World Health Organization, 2002.
3. Gueffiyer F, Boutitie F, Boissel J-P, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomised controlled trials. Ann Intern Med 1997; 126: 761–67.
4. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium-antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955–64.
5. Psaty B, Smith N, Siscovick D, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45.
6. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71.
7. Garg R, Yusuf S. Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–56.
8. Flather M, Yusuf S, Kober L, et al. Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000; 355: 1575-81.
9. Pahor M, Psaty B, Alderman M, et al. Health outcomes associated with calcium-antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949–54.
10. Psaty B, Lumley T, Furberg C, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003; 289: 2534–44.
11. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998; 16: 127–37.
12. Lithell H, Hansson L, Skogg I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21: 875–86.
13. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
14. Brenner B, Cooper M, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–69.
15. Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75.
17. Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
18. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calciumantagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–33.
19. Mac Mahon S, Sharpe N, Gamble G, et al. Randomised, placebocontrolled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J Am Coll Cardiol 2000; 36: 438–43.
20. Pitt B, Byington R, Furberg C, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–10.
21. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
22. Teo K, Burton J, Buller C, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748–54.
23. Staessen J, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension in Europe. Lancet 1997; 350: 757–64.
24. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
25. Zanchetti A, Agabiti-Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomised treatment with either verapamil or chlorthalidone on intima-media thickness. J Hypertens 1998; 16: 1667–76.
26. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
27. Pitt B, O’Neill B, Feldman R, et al. The QUinapril Ischaemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischaemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87: 1058–63.
28. Dens J, Desmet W, Coussement P, et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). Am J Cardiol 2001; 87: 28–33.
29. Wright J, Bakris G, Green T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288: 2421–31.
30. Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Gifford N, Schrier R. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–52.
31. Schrier R, Estacio R, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086–97.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981–97.
33. Wing L, Reid C, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92.
34. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–16.
35. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751–56.
36. Black H, Elliot W, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003; 289: 2073–82.
37. Zanchetti A, Bond M, Hennig M, et al. Calcium-antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation 2002; 106: 2422–27.
38. Brown M, Palmer C, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72.
39. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium-antagonists compared with diuretics and blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–65.
40. Malacco E, Marcia G, Rapelli A, Menotti A, Zuccaro M, Coppini A for the Shell Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160–67.
41. Yui Y, Sumiyoshi T, Kodama K. Long-term effects of nifedipine retard vs ACE inhibitors in hypertension with coronary heart disease: final report of JMIC-B. Circ J 2002; 66 (suppl): 357.
42. Woodward M. Epidemiology, study design and data analysis. London: Chapman and Hall, 1999.
43. Whitehead A, Whitehead J. A general parametric approach to the metaanalysis of randomized clinical trials. Stat Med 1991; 10: 1665–1677.
44. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.
45. Cohn J, Ziesche S, Loss L, Anderson G, and the V-He FT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-Heft III. Circulation 1995; 92: 1–143.
46. Carson P, O’Connor C, Miller A, et al. Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. J Am Coll Cardiol 2000; 36: 541–46.
47. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium-antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105–15.
48. Mac Mahon S, Collins R, Chalmers J. Reliable and unbiased assessment of the effects of calcium-antagonists: importance of minimizing both systematic and random errors. J Hypertens 1997; 15: 1201–04.
49. Collins R, Peto R, Mac Mahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–39.
50. Collins R, Mac Mahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–98.
51. Guidelines Committee. European Society of Hypertension–European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
52. Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.